Transthyretin Amyloidosis Treatment Market to Grow with a CAGR of 7.26% through 2030
Improving Healthcare Access is expected to drive the Global
Transthyretin Amyloidosis Treatment Market growth in the forecast period, 2026-2030.
According to TechSci Research report, “Transthyretin Amyloidosis Treatment- Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2030F”, the Global
Transthyretin Amyloidosis Treatment Market stood at USD 4.95 Billion in 2024 and is
anticipated to grow with a CAGR of 7.26% through 2030. Numerous
countries, particularly in emerging markets, are significantly enhancing their
healthcare infrastructure, including the establishment of specialized treatment
centers, advanced diagnostic facilities, and the integration of innovative
medical technologies. These advancements allow for earlier diagnoses and
improved access to effective treatments for rare diseases like transthyretin amyloidosis (ATTR).
Governments are dedicating more resources to enhance healthcare access,
particularly in underserved areas, by expanding public health programs,
providing subsidies for rare disease treatments, and increasing coverage for
orphan drugs. This makes treatments for conditions like ATTR more widely
accessible. The growth of telemedicine and remote healthcare services has also
improved access to specialist care for patients in rural or less developed
regions, promoting earlier diagnosis and better disease management. In regions
such as North America and Europe, expanding health insurance coverage for rare
disease treatments, including ATTR therapies, has made these treatments more
affordable and available to patients. Furthermore, pharmaceutical companies are
collaborating with local healthcare providers, governments, and NGOs to ensure
broader access to ATTR treatments, enhancing distribution networks and raising
awareness among healthcare professionals. Improved healthcare access enables
more patients to receive early diagnoses, effective treatments, and ongoing
care for conditions like ATTR, driving demand for innovative therapies and
fostering market growth.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on " Global Transthyretin Amyloidosis Treatment Market”
Global Transthyretin Amyloidosis Treatment Market is
segmented into type, therapy, disease type, distribution channel, regional
distribution, and company.
Based on Therapy, Targeted therapy emerged as the dominating segment
in the global market for Transthyretin Amyloidosis Treatment in 2024. Targeted
therapies like Onpattro (patisiran), Inotersen, and Vyndaqel/Vyndamax
(tafamidis) directly tackle the root cause of ATTR by stabilizing or silencing
the transthyretin (TTR) protein. These treatments prevent TTR misfolding and
the formation of amyloid deposits, effectively slowing or halting disease
progression, which results in significant clinical improvements. This makes
them highly effective for managing both ATTR-CM (cardiomyopathy) and ATTR-PN
(polyneuropathy). With proven efficacy in clinical trials, Vyndaqel/Vyndamax
and Onpattro have received approval from regulatory agencies like the FDA and EMA,
showing their ability to reduce symptoms, improve heart and nerve function, and
even extend survival, driving widespread adoption by healthcare providers.
Because these therapies target the root cause of ATTR, they are in high demand
and prioritized over supportive therapies, which only manage symptoms without
addressing disease progression. As a result, targeted therapies have become a
critical component of the treatment plan. The emergence of new therapies in the
pipeline, such as gene editing and RNA silencing technologies, is expected to
further expand treatment options and solidify the dominance of this category.
These therapies represent a significant breakthrough in the treatment of a rare
and debilitating disease, making them the central focus for both pharmaceutical
companies and healthcare providers.
Based on Region, the Asia Pacific region is expected
to be fastest growing region during the forecast period in global Transthyretin Amyloidosis
Treatment market. As healthcare infrastructure continues to improve across the APAC
region, awareness of rare diseases such as ATTR is increasing. Advancements in
diagnostic technologies, including genetic testing and imaging, are enabling
earlier and more accurate diagnoses of ATTR, resulting in more patients being
identified and treated. With rapidly aging populations in countries like Japan
and China, the incidence of wild-type ATTR (ATTRwt), which primarily affects
older individuals, is expected to rise, further driving the demand for
treatments. APAC nations, including India, China, and Japan, are investing
significantly in healthcare infrastructure, expanding access to advanced
treatments, specialized care, and clinical trials, all of which contribute to
the growing ATTR treatment market. Additionally, the region's expanding
pharmaceutical industry, including both local manufacturers and multinational
companies, is increasing the availability of innovative therapies and enhancing
the market penetration of drugs like Onpattro, Vyndaqel/Vyndamax, and others.
As economic prosperity rises in these countries, more patients are able to
afford these high-cost therapies, further fueling market growth. The increasing
focus on rare diseases, coupled with the growing recognition of ATTR as a
serious condition, is prompting pharmaceutical companies to invest more in
treatment development, accelerating the growth of the ATTR treatment market in
APAC.
Major companies operating in Global Transthyretin Amyloidosis Treatment Market are:
- Pfizer Inc.
- Johnson &
Johnson Services Inc.
- Ionis
Pharmaceuticals Inc.
- Alnylam
Pharmaceuticals Inc.
- BridgeBio Pharma
Inc.
- Bristol-Myers
Squibb Company.
- Acrotech
Biopharma.
- AstraZeneca Plc.
- SOM Biotech.
Download Free Sample Report
Customers can also request for 10%
free customization on this report
“The global ATTR treatment market is entering a
transformative phase, where the convergence of cutting-edge biotechnology,
enhanced diagnostics, and increasing disease awareness is reshaping patient
care. New treatment modalities, such as gene therapies and advanced
stabilization agents, are moving beyond symptomatic relief to address the
underlying causes of the disease, positioning the market for long-term growth.
Additionally, growing collaborations between biopharmaceutical companies and
healthcare providers are improving access to treatments across both developed
and emerging regions. While high treatment costs remain a barrier, the ongoing
shift toward more inclusive healthcare policies and innovative reimbursement
models offers a promising pathway for broader market adoption and improved
patient outcomes worldwide”, said Mr. Karan Chechi, Research Director of
TechSci Research, a research-based management consulting firm.
“Transthyretin Amyloidosis Treatment Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type
(ATTR-PN, ATTR-CM), By Therapy (Targeted Therapy (Onpattro, Inotersen,
Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy), By Disease Type
(Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed
Type), Wild Type Amyloidosis), By Distribution Channel (Hospital Pharmacies,
Specialty Pharmacies, Retail Pharmacies, Online Pharmacies), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global
Transthyretin Amyloidosis Treatment Market and provides statistics &
information on market size, structure, and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Transthyretin Amyloidosis Treatment Market.
Contact
TechSci Research
LLC
420 Lexington
Avenue, Suite 300,
New York, United
States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com